Galectin Therapeutics Q3 EPS $(0.04) Beats $(0.05) Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 69.23 percent increase over losses of $(0.13) per share
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 69.23 percent increase over losses of $(0.13) per share from the same period last year.
